SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).

@article{Petrylak2004SWOG9R,
  title={SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).},
  author={Daniel Peter Petrylak and Catherine M. Tangen and Maryyum Hussain and Primo N. Lara and J Jones and M E Talpin and Patrick Burch and Gerald Greene and Elizabeth Small and E. David. Crawford},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3}
}
3 Background: The median survival of AIPCA patients (pts) treated with M+P is 10-12 months. Phase I/II trials of AIPCA pts treated with D+E reported survivals of 20-23 months. SWOG 99-16 was designed to compare the survival D+E to M+P. METHODS 770 men with progressive AIPCA were randomized to either Arm 1) Dexamethasone 60 mg premedication; D=60 mg/m2 day(D) 2, E= 280 mg PO D1-5 Q 21 D or Arm 2) M 12 mg/m2 + P 5 mg PO BID q 21 D. Pts were dose escalated to 70 mg/m2 in Arm 1 and 14 mg/m2in Arm… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005
View 13 Excerpts
Highly Influenced

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005

Similar Papers

Loading similar papers…